24-Hour Movement and Atherosclerotic Risk in adults with rheumatoid arthritis
Official title: Physical Activity, Sleep and Sedentary Behavior on Atherosclerotic Risk Outcomes Among People With Rheumatoid Arthritis
Run by São Paulo State University · NCT07774507 · Data updated 2026-11-12
This study tests how daily activity, sitting, and sleep relate to heart-related risk in adults with RA, using wearables and follow-up after a year.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | São Paulo State University Academic / other |
| Locations | 1 site (Presidente Prudente, São Paulo) |
| Status | Recruiting |
| Started | September 1, 2026 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2028 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT07774507 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–65 with a diagnosis of rheumatoid arthritis who can wear an accelerometer and complete study procedures.
✕Probably not a fit
Individuals with established cardiovascular disease or inability to comply with wear-time requirements may have limited benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational cohort study enrolling adults with rheumatoid arthritis to examine how 24-hour movement patterns—physical activity, sedentary time, and sleep—are associated with indicators of atherosclerotic risk at baseline and over 12 months. Participants will wear accelerometers for 7 days, complete health and lifestyle questionnaires, and undergo cardiovascular, body composition, fitness, and blood tests. Assessments occur at baseline and after 12 months to evaluate changes in movement behaviors and their relationship to cardiovascular risk markers. The study aims to clarify whether interdependent daily movement components influence atherosclerotic risk in RA and whether shifting behaviors over time relates to risk changes.
Why it matters
Potential benefit: If successful, findings could inform RA patients and clinicians about how balancing activity, sitting, and sleep may reduce cardiovascular risk.
How similar studies have gone: While 24-hour movement research is growing, longitudinal data in RA populations remain limited, making this study relatively novel but building on general movement-behavior work.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Medical diagnosis of rheumatoid arthritis. * Age between 18 and 65 years. * Provide written informed consent. * Independence in daily living activities defined as a Katz Index score of 5 or 6 points. Exclusion Criteria: * Acute infectious disease at the time of assessment. * Pregnancy or breastfeeding. * Cognitive impairment identified by the Mini-Mental State Examination according to established cutoff values. * History of cardiovascular disease, including coronary artery disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis, or pulmonary embolism. * Use of uncontrolled vasoactive medication. * Inability to comply with accelerometer wear requirements. * Inability to complete study questionnaires or physical assessments. * Invalid accelerometer data according to the study wear-time criteria.
Where it's running
-
Sao Paulo State University
Presidente Prudente, São Paulo, Brazil Recruiting
Study contacts
- Principal investigator: William R Tebar, PhD — São Paulo State University
- Study coordinator: William R Tebar, PhD
- Email: w.tebar@unesp.br
- Phone: 551832295729
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Heart Rate Variability and Rheumatoid Arthritis: What HRV Looks Like with RA
This study checks whether continuous HRV data from an Oura ring can reflect RA disease activity in adults with RA.
-
Discontinuing MTX or LEF in RA Patients on TNF Inhibitors
This trial tests whether stopping methotrexate or leflunomide while continuing a TNF inhibitor is not worse for disease control in adults with rheumatoid arthritis.
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
Integrative AI profiling of chronic RA pain
This study tests whether an AI-driven multiomic and neurophysiological approach can help explain and predict persistent pain in adults with active rheumatoid arthritis.
-
Oxidative Stress and Heart Risk in People with Rheumatoid Arthritis
This study tests whether certain markers of oxidative stress in people with rheumatoid arthritis are linked to subclinical atherosclerosis and arterial stiffness, which could relate to future heart disease risk.
-
Diosmin or Rebamipide as Add‑ons to Standard RA Therapy
This study tests whether adding diosmin or rebamipide to standard rheumatoid arthritis therapy helps patients achieve better control of their disease compared with standard therapy alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.